Cancers, Vol. 16, Pages 1705: Survivin as a Therapeutic Target for the Treatment of Human Cancer
ene
Survivin was initially identified as a member of the inhibitor apoptosis (IAP) protein family and has been shown to play a critical role in the regulation of apoptosis. More recent studies showed that survivin is a component of the chromosome passenger complex and acts as an essential mediator of mitotic progression. Other potential functions of survivin, such as mitochondrial function and autophagy, have also been proposed. Survivin has emerged as an attractive target for cancer therapy because its overexpression has been found in most human cancers and is frequently associated with chemotherapy resistance, recurr...
Source: Cancers - April 27, 2024 Category: Cancer & Oncology Authors: Qiang Wang Mark I. Greene Tags: Review Source Type: research
Cancers, Vol. 16, Pages 1703: Targeting TRPV4 Channels for Cancer Pain Relief
Trevisan
Despite the unique and complex nature of cancer pain, the activation of different ion channels can be related to the initiation and maintenance of pain. The transient receptor potential vanilloid 4 (TRPV4) is a cation channel broadly expressed in sensory afferent neurons. This channel is activated by multiple stimuli to mediate pain perception associated with inflammatory and neuropathic pain. Here, we focused on summarizing the role of TRPV4 in cancer etiology and cancer-induced pain mechanisms. Many studies revealed that the administration of a TRPV4 antagonist and TRPV4 knockdown diminishes nociception in ...
Source: Cancers - April 27, 2024 Category: Cancer & Oncology Authors: Caren Tatiane de David Antoniazzi N áthaly Andrighetto Ruviaro Diulle Spat Peres Patr ícia Rodrigues Fernanda Tibolla Viero Gabriela Trevisan Tags: Review Source Type: research
The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation
CONCLUSION: Normalizing both biomarkers emerged as the most effective predictive marker for the 1-year recurrence rate, regardless of BRCA mutational status. A negative HE4 value can be a useful predictor for 1-year recurrence-free survival in patients with BRCA mutations.PMID:38670560 | DOI:10.3802/jgo.2024.35.e80 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 26, 2024 Category: OBGYN Authors: Young Joo Lee Woojin Kim Soomin Hong Yong Jae Lee Jung-Yun Lee Sang Wun Kim Sunghoon Kim Young Tae Kim Eun Ji Nam Source Type: research
Geographic variation in breast reconstruction surgery after mastectomy for females with breast cancer in Alberta, Canada
CONCLUSION: We found an overall postmastectomy rate of breast reconstruction of 11.9%, and we identified geographic variation. Predictors of reconstruction in Alberta were similar to those previously described in the literature, specifically with patients in rural communities having lower rates of reconstruction than their urban counterparts. These results suggest that further interventions are required to identify the specific barriers to reconstruction within rural communities and to create strategies to ensure equitable access to all residents.PMID:38670581 | PMC:PMC11052580 | DOI:10.1503/cjs.003823 (Source: Canadian Journal of Surgery)
Source: Canadian Journal of Surgery - April 26, 2024 Category: Surgery Authors: Yifu Huang Jenna-Lynn B Senger Lisa Korus Rhonda J Rosychuk Source Type: research
Considerations for medical nutrition therapy management of the critically ill patient with hematological malignancies: A narrative review
Nutr Clin Pract. 2024 Apr 26. doi: 10.1002/ncp.11152. Online ahead of print.ABSTRACTPatients with hematological malignancies (HMs) are more frequently admitted now than in the past to the intensive care unit (ICU) due to more aggressive approaches in primary therapy of HMs and the need for critical care support. Pathophysiological alterations derived from HMs and the different hematological therapies, such as chemotherapy, negatively affect gastrointestinal (GI) function, metabolism, and nutrition status. Further, malnutrition strongly influences outcomes and tolerance of the different hematological therapies. In consequen...
Source: Nutrition in Clinical Practice - April 26, 2024 Category: Nutrition Authors: Juan Carlos Lopez-Delgado Jayshil J Patel Christian Stoppe Stephen A McClave Source Type: research
Emerging From the Haze ™: Pilot Feasibility Study Comparing Two Virtual Formats of a Cognitive Rehabilitation Intervention
Oncol Nurs Forum. 2024 Apr 18;51(3):223-242. doi: 10.1188/24.ONF.223-242.ABSTRACTOBJECTIVES: To gather feasibility and preliminary data comparing two virtual delivery methods for providing Emerging From the Haze™ (Haze) to cancer survivors compared to waitlist control (WLC).SAMPLE & SETTING: Eligible participants (N = 93) reported cancer-related cognitive impairment following chemotherapy for stage I-III solid tumors, Hodgkin lymphoma, or non-Hodgkin lymphoma.METHODS & VARIABLES: A three-arm randomized design was used to compare virtual live group presentation of Haze sessions, virtual prerecorded Haze group sess...
Source: Oncology Nursing Forum - April 26, 2024 Category: Nursing Authors: Jamie S Myers Jeffrey C Wertheimer Jaromme Geebum Kim Jianghua He Celina H Shirazipour Dedrick Hooper Mary Penne Mays Jennifer R Klemp Carli Zegers Arash Asher Source Type: research
Stress and Coping in Patients With Cancer With Depression and Sleep Disturbance
Oncol Nurs Forum. 2024 Apr 18;51(3):243-262. doi: 10.1188/24.ONF.243-262.ABSTRACTOBJECTIVES: To evaluate for differences in global, cancer-specific, and cumulative life stress, as well as resilience and use of various coping strategies among five groups (no depression or sleep disturbance, no depression and moderate sleep disturbance, subsyndromal depression and very high sleep disturbance, moderate depression and moderate sleep disturbance [Both Moderate]; and high depression and very high sleep disturbance [Both High]).SAMPLE & SETTING: Patients (N = 1,331) receiving chemotherapy were recruited from outpatient oncolo...
Source: Oncology Nursing Forum - April 26, 2024 Category: Nursing Authors: Alejandra Calvo-Schimmel Joosun Shin Carolyn S Harris Lisa Morse Steven M Paul Bruce A Cooper Yvette P Conley Fay Wright Marilyn J Hammer Jon D Levine Christine Miaskowski Source Type: research
Chemotherapy-induced nausea and vomiting in pediatric oncology patients: 2023 recommendations from the Supportive Care Committee of the French Society of Cancer in Children and Adolescents
Bull Cancer. 2024 Apr 25:S0007-4551(24)00123-1. doi: 10.1016/j.bulcan.2024.02.017. Online ahead of print.ABSTRACTChemotherapy-induced nausea and vomiting (CINV) are frequent and dreaded side effects in cancer treatments. CINV has a major impact on patient's condition and quality of life. Prophylaxis is tailored to patient's profile and the emetogenic level of their chemotherapy. The aim of this study is to update the recommendations for CINV prevention and management in pediatric onco-hematology for use in France, by adapting the guidelines of the Pediatric Oncology Group of Ontario (POGO). Clinical practice guideline adap...
Source: Bulletin du Cancer - April 26, 2024 Category: Cancer & Oncology Authors: Marie Charlotte Renaux Torres S éverine Bouttefroy Ma ïna Letort-Bertrand V éronique Maurel Samia Mouffak Florian Scott é Florian Slimano Pauline Treguier L Lee Dupuis Marilyne Poir ée Sandrine Thouvenin-Doulet Source Type: research
Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy
CONCLUSIONS: Several iTMEs exist during tumor evolution and NACT impact on iTME is heterogeneous. Clustering analysis of patients, unravels several IC subsets within OC and can guide future personalized approaches. Targeting different checkpoints such as TIM-3, LAG-3 and IDO-1, more prevalent than PD-L1, could more effectively harness anti-tumor immunity in this anti-PD-L1 resistant malignancy.PMID:38669064 | DOI:10.1158/1078-0432.CCR-23-3836 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 26, 2024 Category: Cancer & Oncology Authors: Elisa Yaniz-Galende Qinghe Zeng Juan Francisco Grau-Bejar Christophe Klein F élix Blanc-Durand Audrey Le Formal Eric Pujade-Lauraine Laure Chardin Elodie Edmond Virginie Marty Isabelle Ray-Coquard Florence Joly Gwena ël Ferron Patricia Pautier Dominique Source Type: research
Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC
CONCLUSIONS: We conclude that NK cells, CD4 + PD-1 + Tim-3 + T cells, and CXCL10 levels in pre-treatment peripheral blood may predict the efficacy of combination of ICI/chemotherapy in NSCLC.PMID:38669521 | DOI:10.3233/CBM-230301 (Source: Cancer Biomarkers : Section A of Disease Markers)
Source: Cancer Biomarkers : Section A of Disease Markers - April 26, 2024 Category: Cancer & Oncology Authors: Nozomu Kimura Yoko Tsukita Risa Ebina-Shibuya Eisaku Miyauchi Mitsuhiro Yamada Daisuke Narita Ryota Saito Chihiro Inoue Naoya Fujino Tomohiro Ichikawa Tsutomu Tamada Hisatoshi Sugiura Source Type: research
Differential synergistic effects of palbociclib and doxorubicin on doxorubicin-resistant cancer cells with diverse tumor origins
J Chemother. 2024 Apr 25:1-9. doi: 10.1080/1120009X.2024.2345454. Online ahead of print.ABSTRACTPalbociclib is a dual inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Palbociclib has frequently been studied in breast cancer cells and has also been linked to function of P-glycoprotein (P-gp), main protein responsible for cancer drug resistance. However, the effect of Palbociclib on cancer drug resistance and specifically doxorubicin-resistant cells overexpressing P-gp have limitedly been studied in the literature. Here, we aimed to decipher the possible synergistic effects of Palbociclib and Doxorubicin combination t...
Source: Journal of Chemotherapy - April 26, 2024 Category: Cancer & Oncology Authors: Gizem Damla Yalcin Pelin Mutlu Hasan Huseyin Kazan Ufuk Gunduz Source Type: research
Longitudinal brain volumetrics in glioma survivors
CONCLUSIONS: This study demonstrated volume loss in contralateral brain structures among LGG survivors, and patients who received RT experienced greater volume loss than those who did not. The results of this study may help to provide context for cognitive outcome research in LGG survivors and inform the design of future strategies to preserve cognition.PMID:38669700 | DOI:10.3171/2024.1.JNS231980 (Source: Journal of Neurosurgery)
Source: Journal of Neurosurgery - April 26, 2024 Category: Neurosurgery Authors: Andrew M McDonald Donna L Murdaugh Katherine A Heinzman Rex A Cardan Jessica Jacob John B Fiveash L Burt Nabors Courtney A Cooper John M Hoyle Desmin Milner Carlos E Cardenas Source Type: research
Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC
CONCLUSIONS: We conclude that NK cells, CD4 + PD-1 + Tim-3 + T cells, and CXCL10 levels in pre-treatment peripheral blood may predict the efficacy of combination of ICI/chemotherapy in NSCLC.PMID:38669521 | DOI:10.3233/CBM-230301 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - April 26, 2024 Category: Cancer & Oncology Authors: Nozomu Kimura Yoko Tsukita Risa Ebina-Shibuya Eisaku Miyauchi Mitsuhiro Yamada Daisuke Narita Ryota Saito Chihiro Inoue Naoya Fujino Tomohiro Ichikawa Tsutomu Tamada Hisatoshi Sugiura Source Type: research
Visceral Leishmaniasis Masquerading as Drug-Induced Pancytopenia in Lung Cancer Patients
Curr Oncol. 2024 Apr 17;31(4):2274-2277. doi: 10.3390/curroncol31040168.ABSTRACTMaintenance chemotherapy is a standard treatment in patients with non-progressive advance staged IV non-squamous non-small cell lung cancer after induction therapy. Here, we report the case of a 53-year-old man undergoing a maintenance monotherapy with pemetrexed who presented prolonged pancytopenia despite filgrastim injections. A bone marrow aspiration revealed a macrophage activation syndrome with Leishmania amastigotes. A Polymerase Chest Reaction testing confirmed the diagnosis of visceral leishmaniasis. Treatment with liposomal amphoteric...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Sophie Laroumagne Julie Tronchetti Herv é Dutau Philippe Astoul Source Type: research
Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia
Curr Oncol. 2024 Apr 9;31(4):2145-2157. doi: 10.3390/curroncol31040159.ABSTRACTNon-small-cell lung cancer (NSCLC) has experienced several diagnostic and therapeutic changes over the past two decades. However, there are few studies conducted with real-world data regarding the evolution of the cost of these new drugs and the corresponding changes in the survival of these patients. We collected data on patients diagnosed with NSCLC from the tumor registry of the University Hospital of Vic from 2002 to 2021. We analyzed the epidemiological and pathological characteristics of these patients, the diverse oncological treatments a...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Marta Parera Roig David Compte Colom é Gemma Basaga ña Colomer Emilia Gabriela Sardo Mauricio Alejandro Tournour Silvia Gri ñó Fernández Arturo Ivan Ominetti Emma Puigoriol Juvanteny Jos é Luis Molinero Polo Daniel Badia Jobal Nadia Espejo-Herrera Source Type: research
